pre-clinical research
Advisory support to determine starting dose, conduct IND-enabling studies and development of required evidence
-1.png?width=414&height=308&name=image%20(2)-1.png)
Trusted Regulatory and Product Development Expertise
Prior to being used in a human, researchers perform testing in controlled laboratory settings. Results during this phase provide researchers with important information about the potential uses in humans and attempts to reduce risk of harm in people. While it is almost never possible to eliminate risk entirely, risk management evaluation can be performed. ProPharma’s expertise spans across the following Pre-clinical Research competencies:
- Translational/Pre-clinical Work
- Lead Optimization
- IND/CTA Enabling Studies
- Program Design & Planning
Pre-Clinical Research Services
ProPharma provides advisory support to determine starting dose, conduct IND-enabling studies and development of required evidence. Our robust team of experts will provide the guidance you and your team needs to ensure good laboratory practices (GLP) and will tailor services based on your specific needs.

pre-clinical research
Translational / Pre-Clinical Work
Our translational/ pre-clinical service offerings help move your from discovery to IND prep and submission with confidence and ease. We provide services that meet global requirements across IND-enabling and NDA-enabling that meet global regulatory requirements for molecules of all sizes.
Our solutions include:
- Manufacture of drug substance (DS)/active pharmaceutical ingredient (API)
- Dosage design
- Analytical and bioanalytical methods development and validation
- Pharmacokinetics
- Toxicology, both safety and genetic toxicology
- Good manufacturing practice (GMP).
We partner with you to ensure a frictionless transition to first-in-human trials.
Lead Optimization
As the last step in the pre-clinical development process, lead optimization is a crucial step for a drug candidate to move into future clinical development. We help you move through the process rapidly and with expert guidance to ensure the most promising compounds are optimized, improving the success probability for your drug candidates. Move confidently from lead optimization to IND study with our comprehensive suite of services and customizable solutions.
IND/CTA Enabling Studies
An investigational new drug (IND) and clinical trial application (CTA) must be completed in both the USA and Europe to progress a compound to first-in-human clinical trials. Successful completion of IND/CTA enabling studies provides detailed analyses for health authority review and allows for formal application submission(s) with the FDA and/or EMA. Health authority requirements vary by region, so it is critical to understand the specific needs of each before IND/CTA enabling studies are designed and planned. Gaining a full understanding of the requirements of each health authority will enable optimal resource allocation and spend.
ProPharma’s proven track record with designing and performing IND/CTA preclinical studies enables your team to achieve speed and efficiency with submissions for first-in-human clinical trials.
Program Design & Planning
A well researched strategic roadmap is essential when beginning a new drug development program. This process will enable efficiency, reduce timelines and costs and can potentially increase the probability of success for the program. ProPharma’s diverse team of experts can assist you and your team across target product profile (TPP), regulatory, non-clinical and clinical, manufacturing, and commercial plans. Ensuring all of these components are considered and incorporated into a seamless strategic document plan is the first step in moving towards achieving your program’s objectives.
News & Insights

March 27, 2023
The Future of UK Clinical Research Delivery
ProPharma applauds the myriad of recent, positive developments for clinical trials in the UK, representing the biggest overhaul in UK clinical trials in two decades. Lord O’Shaughnessy Clinical Trial...

March 9, 2023
MoCRA 2022: Updated Requirements for Cosmetic Companies
MoCRA enacts the most significant expansion of the US FDA to regulate cosmetics since 1938. After 85 years of effectiveness the Modernization of Cosmetics Regulation Act of 2022 or "MoCRA" was...

March 1, 2023
ProPharma Announces the Appointment of Karl Deonanan as New Chief Financial Officer
Raleigh, NC, March 1, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and quality services for the life sciences industry and a portfolio company of Odyssey...
February 6, 2023
ProPharma buys DLC in latest services-focused takeover
On January 31st, 2023, Clinical Insider, a weekly clinical trials newsletter, published a blog post mentioning ProPharma's recent acquisition of Digital Lab Consulting (DLC) and ProPharma's release...

May 3, 2022
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook A Customer-Centric Approach to Clinical Research Solutions ProPharma Group is honored to be named Top 10 CRO 2022 by Pharma Tech Outlook...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded “Best Pharmaceutical Regulatory & Compliance...

June 10, 2022
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

August 31, 2022
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma Group offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma Group’s Compliance and Quality team completed the...
News & Insights

March 01, 2023
ProPharma Announces the Appointment of Karl Deonanan as New Chief Financial Officer
Raleigh, NC, March 1, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and quality services for the life sciences industry and a portfolio company of Odyssey...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded “Best Pharmaceutical Regulatory & Compliance...

Mar 9, 2023 5:00:00 AM
MoCRA 2022: Updated Requirements for Cosmetic Companies
MoCRA enacts the most significant expansion of the US FDA to regulate cosmetics since 1938. After 85 years of effectiveness the Modernization of Cosmetics Regulation Act of 2022 or "MoCRA" was...

Mar 1, 2023 3:00:00 PM
Challenges in Clinical Development of Products for Rare Disease
Rare diseases are defined in the Orphan Drug Act as diseases or conditions that affect less than 200,000 people in the United States. There are over 7,000 rare diseases affecting more than 30 million...

October 14, 2021
Accelerate European Market Access with Compliant and Comprehensive MAA Submission
Preparedness for Marketing Authorization Application (MAA) approval ensures an efficient application process and follow-up. Placing a medicinal product in the European market requires a license for...

March 18, 2022
Outsourcing QA - Reduce Time and Expense While Meeting Critical Requirements
There is a tendency for VPCs to rely solely on the QC/QA units within their outsourced CMO to perform quality functions. However, the sponsor organization has the ultimate responsibility for product...

October 14, 2021
Dedicated Project Manager Directs Regulatory Activities Throughout European Economic Area
Learn how a single point of contact oversaw local regulatory affairs activities across all 31 countries of the EEA. You’re developing a drug, biologic, or medical device product. There are a lot of...

September 1, 2022
Webinar: AI-Powered MI Contact Centers: Key Considerations for a Scalable & Global Medical Information Capability
Today's Medical Information (MI) industry is being driven by evolving customer behavior requiring a more rapid, omnichannel, and digital response to customer needs. The expectation for higher...

October 14, 2021
Ensure Successful Acquisitions with Complete and Accurate Regulatory Due Diligence
Ensure you have as much information as possible to thoroughly evaluate the potential investment when acquiring a company or product. When considering the acquisition of a new company or product, it...

October 14, 2021
Ensure Successful Batch Release, Regulatory Compliance with Experienced Qualified Persons
Streamlining a CMO’s manufacturing process helped ensure GMP compliance for EU batch release and USA inspection readiness. A contract manufacturing organization (CMO) needs to have a reliable quality...

October 4, 2021
How to Minimize Overdue Deviations: A Multi-Site Process Improvement Approach
A global biopharmaceutical client with multiple sites operating under a Warning Letter from the U.S. Food and Drug Administration (FDA) needed significant cross-functional support to meet remediation...

October 14, 2021
Identify At-Risk Drug Products and Ensure Compliance Before Nitrosamines Deadline
Risk evaluation of products containing chemically synthesized APIs must be done to assess adherence to nitrosamine regulations. Marketing Authorization Holders (MAHs) must perform a risk evaluation...

October 4, 2021
Increased Visibility for Senior Management with Custom PMO Design, Implementation
Time. Regardless of company size and the number of products in your portfolio, time is one thing we could all use more of. However, the more projects you have in your portfolio, the more stretched...

October 14, 2021
Initiating Enrollment for Accelerated COVID-19 Treatment Studies in 6 Days
In May 2020, as the FDA released new guidelines to accelerate the development of novel COVID-19 therapeutics and vaccines, our Clinical Services experts were asked to provide independent Data Safety...

October 14, 2021
MICC Overflow Solution Was Successfully Deployed and Preserved Customer Satisfaction
A routine safety letter to HCPs was misinterpreted by recipients, causing a “recall-like” crisis event for a multinational pharmaceutical client. When a routine safety letter to healthcare...

March 27, 2023
Insider Talks - The Journey of ATMPs From the Discovery to Routine GMP Real Life
In the competitive and fast-moving Cell and Gene Therapy (CGT) field, developers face a range of scientific, technical, and regulatory challenges that can quickly become overwhelming and costly. In...

May 19, 2022
Insider Talks - Tips to Adapt to Today’s Auditing Environment, an Auditor’s Perspective
As businesses face the shared global challenges of adapting to new operating models triggered by the recent pandemic, regulated drug and device sponsors, marketing authorization holders, and...

March 25, 2022
Insider Talks - To Decentralize or Not to Decentralize … That is the Question
Having a decentralized approach is critical to ensuring continuity in the face of disaster, and important in meeting your overall enrollment goals while increasing patient diversity. Join us for our...

October 14, 2021
Secure Timely Product Launch by Ensuring GDP Compliance Across Europe
Our client was in the phase of submitting a Marketing Authorization Application (MAA) in the EU and needed to apply for a Wholesale Distribution Authorization (WDA). After application and approval of...

October 14, 2021
Transfer and Manage Clinical Data Provided by Multiple Third-Party Vendors
Managing and sharing large amounts of clinical data provided by a team of ten plus vendors is extremely challenging and requires meticulous attention to detail and expert-level project management to...

October 14, 2021
Understanding Clinical Trial Requirements for Medical Device Label Extensions
After you have developed an FDA-regulated product and obtained marketing approval, you may think your job is done. However, after all the time, effort, money, and so much more that goes into product...

October 17, 2021
Outsourcing of Medical Information Content Creation: Experience of 100 Clients
The time and effort required to write, review, edit, approve, maintain, distribute, and update Medical Information (MI) documents while retaining an auditable record of the search strategy is a great...

October 4, 2021
Outsourcing Medical Information Services: When to Consider a Dedicated Resource
Outsourcing Medical Information (MI) services can be an effective solution for ensuring the provision of MI services to HCPs and consumers globally. The most cost-effective model for the provision of...
Complex Needs Require Custom Solutions
ProPharma builds solutions at the intersection of innovation and flexibility. We’re here to offer a custom alternative that fits your unique needs. Standout solutions scaled to your size.